Associated Papers
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
40119139 (PubMed )
Supplement: 41698_2025_852_MOESM11_ESM.xlsx › Supplementary_Data_9
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Lucas CG et al.
Neuro-oncology, 2025
39560080 (PubMed )
Supplement: noae214_suppl_supplementary_tables.xlsx › Table_S5
Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy.
Ribierre T et al.
Nature Neuroscience, 2024
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
36044908 (PubMed )
Supplement: gg23-giannikou_suptable1.xlsx › TSC1
A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report.
Shi HS et al.
Visceral Medicine, 2021
Dissecting the genetic basis of focal cortical dysplasia: a large cohort study.
Baldassari S et al.
Acta Neuropathologica, 2019
PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours.
Zhang Z et al.
Oncology Letters, 2017
The evolving genomic landscape of urothelial carcinoma.
Glaser AP et al.
Nature Reviews. Urology, 2017
Bladder Cancer and Genetic Mutations.
Zhang X et al.
Cell Biochemistry and Biophysics, 2015
Genome sequencing identifies a basis for everolimus sensitivity.
Iyer G et al.
Science (new York, N.y.), 2012
Select a paper to view details